3579-85-9

Basic information

• Product Name: N-(4-hydroxyphenyl)cinnamamide
• Synonyms: N-(4-hydroxyphenyl)cinnamamide;N-(4-Hydroxyphenyl)-3-Phenyl-2-Propenamide;N-(4-Hydroxyphenyl)-3-phenylpropenamide
• CAS NO: 3579-85-9
• Molecular Formula: C₁₅H₁₃NO₂
• Molecular Weight: 239.26922
• EINECS: 222-701-2
• Mol File: 3579-85-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 495.4°Cat760mmHg
• Flash Point: 253.4°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 1.94E-10mmHg at 25°C
• Refractive Index: 1.698
• CAS DataBase Reference: N-(4-hydroxyphenyl)cinnamamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-hydroxyphenyl)cinnamamide(3579-85-9)
• EPA Substance Registry System: N-(4-hydroxyphenyl)cinnamamide(3579-85-9)

Safety Data

• Hazardous Substances Data: 3579-85-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C15H13NO2/c17-14-9-7-13(8-10-14)16-15(18)11-6-12-4-2-1-3-5-12/h1-11,17H,(H,16,18)/b11-6+

Upstream product

• 123-30-8 4-amino-phenol 
• 102-92-1 Cinnamoyl chloride 
• 102-92-1 cinnamoyl chloride 
• 538-56-7 3-phenylpropenoic anhydride 
• 140-10-3 (E)-3-phenylacrylic acid 
• 621-82-9 Cinnamic acid 
• 201230-82-2 carbon monoxide 
• 536-74-3 phenylacetylene 

Downstream Products

• 94042-54-3 2,6-bis(1-pyrrolidinylmethyl)-4-cinnamidophenol 

Relevant articles and documents

Simple Synthesis of Amides via Their Acid Chlorides in Aqueous TPGS-750-M

The technology of surfactant chemistry is employed for amide bond construction via the reaction of acyl chlorides with amines in 2 wt % TPGS-750-M aqueous solution. Specifically, this highly efficient method enables a chromatography-free scalable process and recycling of the TPGS-750-M solution.

INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors

Four series of acid amides were synthesized, and through measurement using a fluorogenic substrate assay with human recombinant MMP-1, MMP-2 and MMP-9, compound 3f showed considerable inhibitory activities against MMP-2, MMP-9 and the best selectivity over MMP-1. Preliminary structure-activity relationship analysis indicated that caffeic acid amides with electron-donating groups at para-position of amino phenyl group showed better inhibitory activities and selectivity than those with electron-withdrawing groups, and the presence of adjacent dihydroxy in the caffeoyl group was very important for the MMP-2 and MMP-9 inhibitory activities.